[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer]
- PMID: 7979423
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer]
Abstract
A late phase II clinical study of RP56976 (Docetaxel), a new semisynthetic anticancer agent, was conducted in patients with advanced/recurrent breast cancer. RP56976 (Docetaxel) was in general administered at an intravenous dose of 60 mg/m2 with dose-free intervals of 3-4 weeks. Of the 74 patients enrolled, 64 patients completed the scheduled course of treatment. Three patients showed complete response (CR), 32 patients partial response (PR), 3 patients minor response (MR), 18 patients no change (NC), and 8 patients had progressive disease (PD). The overall response rate was 54.7%. The response rate in patients who previously had received chemotherapy was 55.7%, and the response rate in patients who had resistance to anthracycline agents or who did not respond to previous treatment was 58.7%. Adverse reactions included nausea/vomiting in 38 patients (57.6%), fatigue in 46 patients (69.7%), anorexia in 46 patients (69.7%), fever in 26 patients (39.4%), and alopecia in 60 patients (90.9%), all of which were tolerable. Abnormal laboratory findings included leukopenia (Grade III or more) in 57 patients (86.4%) and neutropenia (Grade III or more) in 56 patients (86.2%). The results show that RP56976 (Docetaxel) is an excellent agent with high antitumor effect for the treatment of advanced/recurrent breast cancer.
Similar articles
-
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.Br J Cancer. 1996 Jan;73(2):210-6. doi: 10.1038/bjc.1996.37. Br J Cancer. 1996. PMID: 8546908 Free PMC article. Clinical Trial.
-
[An early phase II clinical study of RP56976 (docetaxel) in patients with breast cancer].Gan To Kagaku Ryoho. 1994 Oct;21(14):2453-60. Gan To Kagaku Ryoho. 1994. PMID: 7944491 Clinical Trial. Japanese.
-
[An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract].Gan To Kagaku Ryoho. 1994 Oct;21(14):2431-7. Gan To Kagaku Ryoho. 1994. PMID: 7944488 Clinical Trial. Japanese.
-
The taxoids. Comparative clinical pharmacology and therapeutic potential.Drugs. 1998 Jan;55(1):5-30. doi: 10.2165/00003495-199855010-00002. Drugs. 1998. PMID: 9463787 Review.
-
Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.Clin Breast Cancer. 2000 Apr;1(1):32-40; discussion 41-2. doi: 10.3816/CBC.2000.n.002. Clin Breast Cancer. 2000. PMID: 11899388 Review.
Cited by
-
Docetaxel: an update of its use in advanced breast cancer.Drugs. 2000 Mar;59(3):621-51. doi: 10.2165/00003495-200059030-00015. Drugs. 2000. PMID: 10776837 Review.
-
A Multicenter Study of Docetaxel at a Dose of 100 mg/m2 in Japanese Patients with Advanced or Recurrent Breast Cancer.Intern Med. 2021 Apr 15;60(8):1183-1190. doi: 10.2169/internalmedicine.5089-20. Epub 2020 Nov 16. Intern Med. 2021. PMID: 33191320 Free PMC article.
-
A phase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer.Br J Cancer. 1998 Jun;77(11):1937-43. doi: 10.1038/bjc.1998.321. Br J Cancer. 1998. PMID: 9667671 Free PMC article. Clinical Trial.
-
Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.Int J Clin Oncol. 2013 Feb;18(1):96-104. doi: 10.1007/s10147-011-0349-5. Epub 2011 Nov 18. Int J Clin Oncol. 2013. PMID: 22095245
-
Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.Drugs. 1996 Jun;51(6):1075-92. doi: 10.2165/00003495-199651060-00011. Drugs. 1996. PMID: 8736622 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials